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CTLA-4 plays an important role in the immune system as a T cell inhibitory factor. This inhibitory signal not only determines whether T cells become activated, but also affects the clonal representation in an immune response. CTLA-4 regulates cell cycle progression rather than directly the induction of apoptosis.
1 CTLA-4 Ig and anti-CTLA-4 have been applied for the treatment of both autoimmune diseases and cancers.
Little is known about the regulatory mechanism for CTLA-4 expression. Polymorphisms in the Ctla-4 are associated with several autoimmune diseases, and polymorphisms at certain locations of the Ctla-4 might conceivably affect its expression. We have described a higher prevalence of thymine at position −318 of the Ctla-4 promoter (−318T) in patients with Wegener's granulomatosis. 2 Recently, Ligers and colleagues reported that individuals carrying −318T exhibited significantly increased expression both of cell-surface CTLA-4 in activated cells and of Ctla-4 mRNA in non-stimulated cells, 3 suggesting a potential role for the CЈ T transition in the regulation of expression. In the present study, we examined the effect of CЈ T switch at −318 on the Ctla-4 promoter activity. Our results demonstrated that the −318T allele was associated with a significantly higher promoter activity than the −318C allele. 
Results and discussion
To determine whether the CЈ T transition at position −318 transcriptionally regulates the Ctla-4 gene expression, we made two Ctla-4 promoter reporter constructs which contained C and T alleles, respectively. As shown in Figure  1 , the −318T allele was associated with a higher promoter activity than the −318C allele (8.13 ± 0.46 vs 6.87 ± 0.49). This result was also confirmed in the THP-1 cell line transfected with these two reporter constructs, and stimulated with IFN-␥ (5 mg/ml) and PMA (10 ng/ml).
Our allele-specific transcription data indicate that the −318T allele is associated with higher transcriptional activity than the −318C allele. The -318T allele could be considered as protective against autoimmune reactions. Our results could explain the increased expression of CTLA-4 3 and the observed associations of the −318T allele to some diseases. 4 Homozygosity for −318/T in the promoter of Ctla-4 is rarely present in a Caucasian population. [4] [5] [6] [7] In our previous study, the frequencies of individuals with genotypes −318C/C, C/T, and T/T were 86%, 17% and 0%, respectively, in healthy individuals (n = 122) and 69%, 31%, 0%, respectively, in patients with Wegener's granulomatosis (n = 32). When we considered the prevalence of longer (AT)n in the 3Ј-untranslated region together with the promoter single nucleotide polymorphism (SNP), we found that all patients carrying the −318T allele were homozygous for (AT)n Ͼ86 bp alleles. 2 As the longer (AT)n alleles are associated with decreased mRNA stability and thus decreased protein expression, the −318T mutation should counteract the effects of long (AT)n alleles. The −318T mutation could thus be regarded as protective against increased T cell stimulation.
In conclusion, the CЈ T transition at position −318 transcriptionally regulates the Ctla-4 gene expression and the Figure 1 Relative promoter activity of the human Ctla-4 gene in Jurkat T cells. Genomic DNA was used to amplify a 329-bp fragment covering the −318 polymorphic site. The following primers were used: −318C forward: AGG GGT ACC ACT TAG TTA TCC AGA TCC TCA AAG, −318T forward: AGG GGT ACC ACT TAG TTA TCC AGA TCC TTA AAG, and reverse: AG CGC TCG AGC CAG GTT CAG. The amplieid fragments (318C and −318T alleles) were subcloned into a TA cloning vector (PCRII; In Vitrogen, Leek, The Netherlands). The sequence of inserted fragment was confirmed by sequence analysis using the ABI-PRISM Terminator Cycle Ready Reaction Kit (Perkin Elmer, Foster City, CA, USA). Each fragment was then inserted upstream of the firely luciferase reporter gene at the KpnI/XhoI sites of the PGL3-basic vector (Promega, Madison, WI, USA). Jurkat T cells were maintained in complete medium (CM) (RMPI1640 medium supplemented with 10% fetal bovine serum, 2 mM glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin) at 37°C under 5% CO 2 . Transfection experiments were conducted using the FuGENE 6 Transfection Reagent from Roche Molecular Biochemical (Stockholm, Sweden). Twenty-five thousand cells were seeded with 1 mg of constructs and 100 ng of pRL.CMV (a Renilla-based luciferase construct, Promega) per-well. After 24 h, the cells were stimulated with ConA (5 mg/ml), PMA (10 ng/ml) and harvested after 48 h. Dual-Luciferase Report assay system (Promega) was applied according to the manufacturer's instructions. The luciferase activity was measured using a Turner luminometer (TD-20/20). Firefly luciferase activity was normalized to Renilla luciferase activity to correct for variations in transfection efficiency. The relative luciferase levels were obtained from three assays performed in duplicate.
